Expression and Clinical Significance of Sclerostin and RANKL in Multiple Myeloma Patients
Objective:To investigate the expression levels of sclerostin and receptor activator of NF-κB ligand(RANKL)in bone marrow supernatant of multiple myeloma(MM)patients and their clinical significance.Methods:60 patients with MM from January 2018 to June 2020 were collected as research objects.Based on the International Staging System(ISS),patients with MM were divided into ISS stage Ⅰ,Ⅱ and Ⅲ stages,including 18 patients with ISS stage Ⅰ,23 patients with ISS stage Ⅱ and 19 patients with ISS stage Ⅲ.At the same time,58 patients who proved that their bone marrow function was normal through bone marrow aspiration and non-hematological diseases were included as the control group.The clinicopathological data of MM patients including age,sex,body mass index(BMI),corrected blood calcium,bone in-jury,C-reactive protein and lactate dehydrogenase were collected and sorted.The expression levels of sclerostin and RANKL in bone marrow of MM group and control group were detected and compared.The expression levels of sclerostin and RANKL in bone marrow of MM patients with different ISS stages were analyzed.The correlation between the expres-sion levels of RANKL and sclerostin in bone marrow of MM patients was analyzed by Pearson grade correlation.Kaplan-Meier method was used to analyze the relationship between the expression levels of sclerostin and RANKL in bone marrow and the three-year survival rate of MM patients.Results:Compared with control group,the expression levels of sclerostin and RANKL in bone marrow of MM group were significantly increased(P＜0.05).The clinicopathological characteristics of MM patients showed that the expression levels of sclerostin and RANKL in bone marrow were closely correlated with corrected blood calcium,C-reactive protein and lactate dehydrogenase(P＜0.05).There were significant differences in the expression levels of bone marrow sclerostin and RANKL in MM patients with different ISS stages(P＜0.05).Compared with patients with ISS stage Ⅰ and Ⅱ,the expression levels of bone marrow sclerostin and RANKL were significantly in-creased in patients with ISS stage Ⅲ(P＜0.05).The expression levels of sclerostin and RANKL in bone marrow of ISS stage Ⅱ patients were significantly higher than those of ISS stage Ⅰ MM patients(P＜0.05).Pearson grade correlation analysis showed that the expression levels of bone marrow sclerostin and RANKL were positively correlated in MM pa-tients(r=0.551,P＜0.001).Kaplan-Meier results showed that the 3-year survival rate of patients with high expression of sclerostin in bone marrow was lower than that of patients with low expression of RANKL(x2=3.916,P＜0.05),and the 3-year survival rate of patients with high expression of RANKL in bone marrow was lower than that of patients with low expression of RANKL(x2=4.223,P＜0.05).Conclusion:The expression levels of sclerostin and RANKL in bone marrow of MM patients were significantly increased,and both of them had important clinical application value in predicting the prognosis of MM patients.
multiple myelomasclerostinreceptor activator of NF-κB ligandclinicopathological features
NETL
NSTL
万方数据
